CLINICAL RESEARCH
Polymorphism of IL28B gene and response to pegylated interferon α2a in chronic hepatitis B
Submission date: 2017-02-19
Acceptance date: 2017-03-14
Publication date: 2017-03-29
Arch Med Sci Civil Dis 2017;2(1):70-77
KEYWORDS
TOPICS
ABSTRACT
Introduction: Because of its worldwide prevalence, chronic hepatitis B constitutes a significant global health issue. Chronic hepatitis B virus (HBV) infection affects about 350 million people, with 1 million deaths annually due to its sequelae. The unique way of replication makes HBV difficult to eradicate with the available treatment. Interferon is currently the only option offering a “curative treatment strategy”. Predictors of a sustained response to interferon are desired. The aim of this study was to assess the efficacy of chronic hepatitis B treatment with pegylated interferon 2a in relation to the polymorphisms of the interleukin 28B gene.
Material and methods: Eighty-six patients were included in the study. They were treated with PegIFN2a in the dose of 180 µg weekly for 48 weeks and were followed up for at least 1 year after the end of therapy (EOT). Treatment efficacy was defined as HBsAg clearance or HBV viral load ≤ 2000 IU/ml at the end of therapy and at the end of 12 consecutive months. Two polymorphisms of IL28B at loci rs12979860 and rs809997 were examined in every patient.
Results: No associations between any of the IL28B polymorphisms and HBsAg elimination were found. However, a weak but statistically significant association between persistent HBV-DNA decrease and a TT variant (C/T) of IL28B was found (Spearman’s correlation coefficient 0.236, p < 0.001). Patients having this polymorphism also had significantly lower HBV-DNA loads after EOT (Spearman’s correlation coefficient 0.27, p = 0.02). The weak associations and small number of patients do not allow us to draw firm conclusions.
Conclusions: We discovered no associations between any of the IL28B polymorphisms and HBsAg loss, IL28B polymorphisms do not seem to play an important role as predictors of treatment efficacy in the treatment of chronic B hepatitis with pegylated interferon.
Material and methods: Eighty-six patients were included in the study. They were treated with PegIFN2a in the dose of 180 µg weekly for 48 weeks and were followed up for at least 1 year after the end of therapy (EOT). Treatment efficacy was defined as HBsAg clearance or HBV viral load ≤ 2000 IU/ml at the end of therapy and at the end of 12 consecutive months. Two polymorphisms of IL28B at loci rs12979860 and rs809997 were examined in every patient.
Results: No associations between any of the IL28B polymorphisms and HBsAg elimination were found. However, a weak but statistically significant association between persistent HBV-DNA decrease and a TT variant (C/T) of IL28B was found (Spearman’s correlation coefficient 0.236, p < 0.001). Patients having this polymorphism also had significantly lower HBV-DNA loads after EOT (Spearman’s correlation coefficient 0.27, p = 0.02). The weak associations and small number of patients do not allow us to draw firm conclusions.
Conclusions: We discovered no associations between any of the IL28B polymorphisms and HBsAg loss, IL28B polymorphisms do not seem to play an important role as predictors of treatment efficacy in the treatment of chronic B hepatitis with pegylated interferon.
REFERENCES (30)
1.
World Health Organization – Global Alert and Response(GAR)/Diseases Covered by GAR/Hepatitis 2013.
2.
European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
3.
Cornberg M, Jaroszewicz J, Manns MP, Wedemeyer H. Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol 2010; 56: 451-65.
4.
Vigano M, Lampertico P. Hepatitis B treatment strategy in 2013: NUC, Peg-IFN or both? Therapy In Liver Diseases, Elsevier Doyma 2013: 95-9.
5.
Perillo R. Benefits and risk of interferon therapy for hepatitis B. Hepatology 2009;49 (Suppl. 5): 103-11.
6.
Lampertico P, Vigano M, Colombo M. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon. Liver Int 2013; 33: 157-63.
7.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
8.
Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
9.
Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology 2010; 139: 120-9.
10.
Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11: 6.
11.
Chalton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-24.
12.
Takahashi T. Interleukin28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol 2014; 20: 12026-30.
13.
Robins GW, Scott LJ, Keating GN. Peginterferon-alpha-2a (40kD): a review of its use in the management of patients with chronic hepatitis B. Drugs 2005; 65: 809-25.
14.
Marcellin P, Piratvisuth T, Brunetto MR, et al. A fine course of Peginterferon alpha-2a results in inactive chronic hepatitis B and HBsAg clearance 5 years post-treatment in patients with HBeAg-negative disease: baseline characteristics and predictive factors of long-term response. Hepatology 2009; 50 (Suppl. 4): 487A.
15.
Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alpha-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
16.
Janssen HL, van Zonnenveld M, Senturk H, et al. Pegylated interferon alfa 2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 123-9.
17.
Marcellin P, Lau GK, Bonino F, et al. Peginterferon alpha-2a alone, lamivudine alone, and two in combination in patients with HBeAg-negative chronic hepatits B. N Engl J Med 2004; 351: 1206-17.
18.
Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006; 26: 373-9.
19.
Sonneveld MJ, Wong WW, Woltman AM, et al. Polymorphisms at rs12979860 and rs12980275 near IL28B predict serological response to (Peg-)interferon in HBeAg-positive chronic hepatitis B. J Hepatol 2011; 54: S32.
20.
Mangia A, Santoro R, Mottola L, et al. Lack of association between IL28B variants and HBsAg clereance after interferon treatment. J Hepatol 2011; 54: S525.
21.
Xiaopan W, Zhenhui X, Xilin Z, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012; 93: 297-300.
22.
Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896.
23.
Kandemir Ö, Fidanci SB, Demir N, Görür A, Tamer L. Chronic hepatitis B and IL28B polymorphism: preliminary study. Mol Biol Rep 2013; 40: 6189-94.
24.
Seto WK, Wong DK, Kopaniszen M, et al. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695-703.
25.
Brouwer WP, Arends P, Rijckborst V, et al. Polymorphisms near the IL28B gene are not associated with response to peginterferon in HBe – negative chronic hepatitis B patients. J Hepatol 2013; 58: S299.
26.
Zhang Q, Lapalus M, Asselah T, et al. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepatitis 2014; 21: 525-32.
27.
Domagalski K, Pawłowska M, Zaleśna A, et al. The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. Eur J Clin Micr Infect Dis 2014; 33: 2025-33.
28.
Wu H, Zhao G, Qian F, et al. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatits B. Liver Int 2015; 35: 473-81.
29.
Galmozzi E, Vigano M, Lampertico P. Systemic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection. Aliment Pharmacol Ther 2014; 39: 569-78.
30.
Lee DH, Lee JH, Kim YJ, et al. Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclereance: a systemic review and meta-analysis. J Viral Hepatits 2014; 21: 163-70.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
